||Azathioprine, an immunosuppressive agent, inhibits purine synthesis and GTP-binding protein Rac1 activation.
||CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
||EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.
||Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.
||NSC 23766 trihydrochloride
||NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by GEFs (IC50: ~50 μM); no inhibitory for the closely related targets, RhoA or Cdc42.
||EHT 1864 is a effective Rac family GTPase inhibitor for Rac1/Rac1b/Rac2/Rac3 (Kd: 40/50/60/250 nM).
||Zoledronate is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hy
||SAR407899 is Rho kinase inhibitor potently inhibits endothelin-1-induced constriction of renal resistance arteries.